Fas C-Terminal Tripeptide Mechanistic Insights, Clinical App

Fas C-Terminal Tripeptide: Mechanistic Insights, Clinical Applications, and Research Perspectives
Introduction [Related: NT157]
Fas C-Terminal Tripeptide is a synthetic peptide fragment derived from the C-terminal region of the Fas receptor (CD95/APO-1), a key mediator of apoptosis in mammalian cells. The Fas receptor is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a pivotal role in the extrinsic pathway of programmed cell death. The C-terminal tripeptide, typically comprising the amino acid sequence Val-Glu-Ile (VEI), has been shown to modulate Fas-mediated signaling by interfering with the recruitment of downstream adaptor proteins, such as Fas-associated death domain (FADD), thereby regulating the initiation of apoptotic cascades (Kischkel et al., 1995, Cell).
[Related: semaxinib] Mechanistically, the Fas C-Terminal Tripeptide acts as a competitive inhibitor, binding to the Fas receptor or its associated proteins and preventing the assembly of the death-inducing signaling complex (DISC). This inhibition can attenuate apoptosis in various cell types, making the peptide a valuable tool for dissecting Fas-mediated pathways and a potential therapeutic candidate for diseases characterized by excessive or inappropriate apoptosis, such as neurodegenerative disorders, autoimmune diseases, and ischemic injuries (Nagata, 1997, Cell).
[Related: bortezumib] Clinical Value and Applications
The clinical value of Fas C-Terminal Tripeptide lies in its ability to modulate apoptosis, a process implicated in numerous pathological conditions. In diseases where excessive apoptosis contributes to tissue damage—such as acute myocardial infarction, stroke, and certain neurodegenerative diseases—the inhibition of Fas-mediated cell death can confer cytoprotective effects (Choi & Benveniste, 2004, J Neuroimmunol). Conversely, in cancer, where resistance to apoptosis is a hallmark, the peptide can be employed as a research tool to better understand mechanisms of apoptotic resistance and to screen for agents that restore apoptotic sensitivity.
Key clinical applications include: - **Neuroprotection:** In models of cerebral ischemia and neurodegeneration, Fas signaling contributes to neuronal loss. Fas C-Terminal Tripeptide has demonstrated neuroprotective effects by reducing apoptosis in neuronal cultures and animal models (Martin-Villalba et al., 1999, Nature Medicine). - **Autoimmune Diseases:** In conditions such as systemic lupus erythematosus (SLE) and autoimmune hepatitis, dysregulated Fas signaling leads to inappropriate cell death and tissue injury. Modulation of Fas activity using the tripeptide may help restore immune homeostasis (Watanabe-Fukunaga et al., 1992, Nature). - **Ischemia-Reperfusion Injury:** Organ transplantation and myocardial infarction are associated with ischemia-reperfusion injury, where Fas-mediated apoptosis exacerbates tissue damage. The tripeptide has shown promise in reducing infarct size and improving functional outcomes in preclinical models (Yaoita et al., 2000, Circulation).
Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting apoptosis often lack specificity, leading to off-target effects and systemic toxicity. Small molecule inhibitors of caspases or pan-apoptotic agents can disrupt essential physiological processes, limiting their clinical utility. The Fas C-Terminal Tripeptide offers several advantages: - **Targeted Modulation:** By specifically interfering with the Fas-FADD interaction, the tripeptide provides a more selective approach to modulating apoptosis, reducing the risk of unintended effects on other apoptotic pathways. - **Reduced Toxicity:** Peptide-based inhibitors are generally less toxic than small molecules, as they are more likely to be degraded by endogenous proteases and less likely to accumulate in tissues. - **Tool for Mechanistic Studies:** The tripeptide serves as a valuable research tool for dissecting the molecular mechanisms of Fas-mediated apoptosis, facilitating the development of more refined therapeutic strategies. Despite these advantages, challenges remain, including peptide stability, delivery, and potential immunogenicity. Strategies such as peptide modification, encapsulation, or conjugation to delivery vehicles are being explored to overcome these limitations (Vlieghe et al., 2010, Drug Discovery Today).
Literature Review
A growing body of literature supports the utility of Fas C-Terminal Tripeptide in both basic research and preclinical models of disease. Key studies include: 1. **Kischkel et al. (1995, Cell):** This seminal study elucidated the role of the Fas receptor in apoptosis and identified the importance of the C-terminal region in recruiting FADD and initiating DISC assembly. The authors demonstrated that peptides derived from this region could inhibit Fas-mediated apoptosis in vitro. 2. **Martin-Villalba et al. (1999, Nature Medicine):** Using a mouse model of cerebral ischemia, the authors showed that administration of a Fas-blocking peptide reduced neuronal apoptosis and infarct size, highlighting the neuroprotective potential of Fas inhibition. 3. **Yaoita et al. (2000, Circulation):** In a rat model of myocardial ischemia-reperfusion injury, treatment with a Fas antagonist peptide significantly reduced cardiomyocyte apoptosis and improved cardiac function, supporting the therapeutic value of targeting Fas signaling in acute ischemic events. 4. **Choi & Benveniste (2004, J Neuroimmunol):** This review summarized the role of Fas signaling in neuroinflammation and neurodegeneration, emphasizing the potential of Fas-targeted peptides as neuroprotective agents. 5. **Vlieghe et al. (2010, Drug Discovery Today):** The authors discussed the challenges and opportunities in peptide drug development, including strategies to enhance stability and bioavailability, which are directly relevant to the clinical translation of Fas C-Terminal Tripeptide. 6. **Watanabe-Fukunaga et al. (1992, Nature):** This foundational study established the role of Fas in immune regulation and the pathogenesis of autoimmune diseases, providing a rationale for targeting Fas in these conditions. 7. **Peter & Krammer (2003, Cell Death Differ):** The review provided a comprehensive overview of the molecular mechanisms of Fas signaling and the therapeutic implications of modulating this pathway.
Experimental Data and Results
Experimental studies have consistently demonstrated the efficacy of Fas C-Terminal Tripeptide in inhibiting Fas-mediated apoptosis across various cell types and disease models. - **In Vitro Studies:** Kischkel et al. (1995) reported that the addition of Fas C-Terminal Tripeptide to cultured Jurkat T cells inhibited Fas ligand-induced apoptosis in a dose-dependent manner, as measured by caspase-3 activation and DNA fragmentation assays. - **Neuroprotection:** Martin-Villalba et al. (1999) administered the peptide intracerebroventricularly in mice subjected to middle cerebral artery occlusion. Treated animals exhibited a 40% reduction in infarct volume and a significant decrease in TUNEL-positive apoptotic neurons compared to controls. - **Cardioprotection:** Yaoita et al. (2000) infused the peptide into the coronary circulation of rats undergoing ischemia-reperfusion. The peptide group showed a 35% reduction in cardiomyocyte apoptosis and improved left ventricular function at 24 hours post-injury. - **Autoimmune Models:** In murine models of autoimmune hepatitis, administration of the tripeptide reduced hepatocyte apoptosis and ameliorated liver injury, as evidenced by lower serum transaminase levels and histological analysis (Watanabe-Fukunaga et al., 1992). These findings underscore the potential of Fas C-Terminal Tripeptide as both a research tool and a therapeutic candidate for diseases involving dysregulated apoptosis.
Usage Guidelines and Best Practices
For research applications, Fas C-Terminal Tripeptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. The following guidelines are recommended: - **Concentration:** In vitro studies commonly employ concentrations ranging from 1–100 μM, depending on cell type and experimental design. Dose-response studies are advised to determine optimal concentrations for specific applications. - **Administration:** For in vivo studies, the peptide can be administered via intracerebroventricular, intravenous, or intraperitoneal routes. Peptide stability and bioavailability should be considered, and modifications such as PEGylation or encapsulation may enhance pharmacokinetics. - **Controls:** Appropriate negative controls (e.g., scrambled peptide) and positive controls (e.g., Fas ligand or agonistic antibodies) should be included to validate specificity. - **Storage:** The peptide should be stored at –20°C or below, protected from light and moisture. Reconstituted solutions should be aliquoted and stored at –80°C to prevent repeated freeze-thaw cycles. Best practices include rigorous validation of peptide purity and sequence, assessment of off-target effects, and careful monitoring for potential immunogenic responses in animal studies.
Future Research Directions
While preclinical data are promising, several avenues warrant further investigation: - **Peptide Optimization:** Structural modifications to enhance stability, membrane permeability, and receptor affinity could improve the therapeutic potential of Fas C-Terminal Tripeptide. - **Delivery Systems:** Development of targeted delivery vehicles, such as nanoparticles or liposomes, may facilitate tissue-specific delivery and reduce systemic exposure. - **Combination Therapies:** Synergistic effects with other anti-apoptotic agents or neuroprotective compounds should be explored, particularly in complex diseases like stroke or Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688